Dexmedetomidine Versus Adenosine: Electrophysiologic Effects and Therapeutic Use for Terminating Supraventricular Tachycardia
Overview
- Phase
- Not Applicable
- Intervention
- Dexmedetomidine
- Conditions
- Supraventricular Tachycardia
- Sponsor
- University of Pittsburgh
- Enrollment
- 22
- Locations
- 1
- Primary Endpoint
- Termination of SVT
- Status
- Completed
- Last Updated
- 9 years ago
Overview
Brief Summary
The purpose of this study is to evaluate the efficacy and safety of dexmedetomidine in the acute termination of Supraventricular Tachycardia (SVT).
Detailed Description
In 2006 the investigator found that dexmedetomidine, an alpha-2 adrenergic agonist with primarily sedative properties, possesses additional anti-arrhythmic properties. So far the investigator has found that dexmedetomidine has the ability to prevent or terminate arrhythmias like atrial ectopic tachycardia (85% success) and junctional ectopic tachycardia (75% success). The most dramatic effect however was observed in the acute termination of reentrant SVT with a success rate of \> 96%. More importantly we found that dexmedetomidine terminates SVT without causing any sinus pause or asystole (frequently seen with adenosine) and thus avoiding the feeling of "impending doom". In this study adenosine is being compared head to head with dexmedetomidine in a cross over study, for both safety and efficacy when given for the termination of SVT in the electrophysiology (EP) lab. Additional EP parameters will be measured to elucidate the exact site of dexmedetomidine's mechanism of action.
Investigators
Gaurav Arora
Assistant Professor
University of Pittsburgh
Eligibility Criteria
Inclusion Criteria
- •Patients between the age of 5 - 30 years old, who are scheduled for cardiac electrophysiology study for evaluation of reentrant SVT
Exclusion Criteria
- •Severe Heart Failure
- •Presence of of any other antiarrhythmic medication within 24 hours of enrollment
- •Third degree heart block
- •Sick Sinus Syndrome
Arms & Interventions
Adenosine and Dexmedetomidine
Patients will receive adenosine and then dexmedetomidine for the termination of SVT
Intervention: Dexmedetomidine
Adenosine and Dexmedetomidine
Patients will receive adenosine and then dexmedetomidine for the termination of SVT
Intervention: Adenosine
Outcomes
Primary Outcomes
Termination of SVT
Time Frame: Within 3 minutes
Number of participants with SVT Termination within 3 minutes of medication administration
Secondary Outcomes
- Number of Participants With Sinus Pause >2.5 Sec After Termination of SVT(1 minute)
- Number of Participants With Tachyarrhythmias After Medication Administration(10 minutes)
- Number of Participants With Hypotension by Non-invasive Cuff in First 10 Minutes After Medication Administration(10 minutes)